Letvin Norman L, Huang Yue, Chakrabarti Bimal K, Xu Ling, Seaman Michael S, Beaudry Kristin, Korioth-Schmitz Birgit, Yu Faye, Rohne Daniela, Martin Kristi L, Miura Ayako, Kong Wing-Pui, Yang Zhi-Yong, Gelman Rebecca S, Golubeva Olga G, Montefiori David C, Mascola John R, Nabel Gary J
Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892-3005, USA.
J Virol. 2004 Jul;78(14):7490-7. doi: 10.1128/JVI.78.14.7490-7497.2004.
Because a strategy to elicit broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies has not yet been found, the role of an Env immunogen in HIV-1 vaccine candidates remains undefined. We sought to determine whether an HIV-1 Env immunogen genetically disparate from the Env of the challenge virus can contribute to protective immunity. We vaccinated Indian-origin rhesus monkeys with Gag-Pol-Nef immunogens, alone or in combination with Env immunogens that were either matched or mismatched with the challenge virus. These animals were then challenged with a pathogenic simian-human immunodeficiency virus. The vaccine regimen included a plasmid DNA prime and replication-defective adenoviral vector boost. Vaccine regimens that included the matched or mismatched Env immunogens conferred better protection against CD4(+) T-lymphocyte loss than that seen with comparable regimens that did not include Env immunogens. This increment in protective immunity was associated with anamnestic Env-specific cellular immunity that developed in the early days following viral challenge. These data suggest that T-lymphocyte immunity to Env can broaden the protective cellular immune response to HIV despite significant sequence diversity of the strains of the Env immunogens and can contribute to immune protection in this AIDS vaccine model.
由于尚未找到诱导产生广泛中和抗1型人类免疫缺陷病毒(HIV-1)抗体的策略,Env免疫原在HIV-1候选疫苗中的作用仍不明确。我们试图确定与攻击病毒的Env基因不同的HIV-1 Env免疫原是否有助于产生保护性免疫。我们用Gag-Pol-Nef免疫原单独或与与攻击病毒匹配或不匹配的Env免疫原联合接种印度裔恒河猴。然后用致病性猿猴-人类免疫缺陷病毒攻击这些动物。疫苗方案包括质粒DNA初免和复制缺陷型腺病毒载体加强免疫。与不包含Env免疫原的类似方案相比,包含匹配或不匹配Env免疫原的疫苗方案对CD4(+) T淋巴细胞损失提供了更好的保护。这种保护性免疫的增强与病毒攻击后早期产生的回忆性Env特异性细胞免疫有关。这些数据表明,尽管Env免疫原毒株存在显著的序列多样性,但针对Env的T淋巴细胞免疫可以拓宽对HIV的保护性细胞免疫反应,并有助于在这种艾滋病疫苗模型中提供免疫保护。